On February 15, 2018, Guardant Health announced that its multi-gene liquid biopsy somatic mutation panel has received the prestigious "Expedited Access Pathway" designation from the FDA.
According to co-founder Helmy Eltouky, "Our FDA submission for Guardant360 is Guardant Health's top priority for 2018." Press release here.
Liquid biopsy is a high visibility space, with 1060 hits currently on Pubmed. FDA and AACR held a conference on the topic a few months ago in October 2017, decks and transcripts here.
Within the field, Guardant Health has been a leading player, having raised an additional $360M in May 2017 (here). According to this week's press release, the value of the Guardant G360 has been supported by >30 clinical outcome studies.
Update: Field of Liquid Biopsy.
On March 15, 2018, Genomeweb had an article detailing the discontinuation of the Oncotype liquid biopsy assay, "citing a shift to tests that are proprietary." Genomeweb (subscription). This announcement had been made in GHDX's early March investor call, if not before. The company also announced a staff downsizing of 10%.